YB-1113
/ YB Life Sci, Bright Cell
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 13, 2025
Safety and Efficacy of YB-1113 in Treatment of POI
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: Bright Cell, Inc. | Trial completion date: Aug 2027 ➔ Aug 2028 | Trial primary completion date: Jul 2026 ➔ Jul 2027
Trial completion date • Trial primary completion date • Women's Health
August 23, 2024
Safety and Efficacy of YB-1113 in Treatment of POI
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: Bright Cell, Inc. | Trial completion date: Aug 2025 ➔ Aug 2027 | Trial primary completion date: Jul 2025 ➔ Jul 2026
Trial completion date • Trial primary completion date • Women's Health
September 27, 2022
Safety and Efficacy of YB-1113 in Treatment of POI
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: YB Life Science, LLC | Phase classification: P1/2 ➔ P1
Phase classification • Women's Health
August 10, 2022
Safety and Efficacy of YB-1113 in Treatment of POI
(clinicaltrials.gov)
- P1/2 | N=6 | Not yet recruiting | Sponsor: YB Life Science, LLC
New P1/2 trial • Women's Health
1 to 4
Of
4
Go to page
1